» Articles » PMID: 39389062

PROTAC-mediated Activation, Rather Than Degradation, of a Nuclear Receptor Reveals Complex Ligand-receptor Interaction Network

Overview
Journal Structure
Publisher Cell Press
Date 2024 Oct 10
PMID 39389062
Authors
Affiliations
Soon will be listed here.
Abstract

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules containing a ligand for a protein of interest linked to an E3 ubiquitin ligase ligand that induce protein degradation through E3 recruitment to the target protein. Small changes in PROTAC linkers can have drastic consequences, including loss of degradation activity, but the structural mechanisms governing such changes are unclear. To study this phenomenon, we screened PROTACs of diverse targeting modalities and identified dTAG-13 as an activator of the xenobiotic-sensing pregnane X receptor (PXR), which promiscuously binds various ligands. Characterization of dTAG-13 analogs and precursors revealed interplay between the PXR-binding moiety, linker, and E3 ligand that altered PXR activity without inducing degradation. A crystal structure of PXR ligand binding domain bound to a precursor ligand showed ligand-induced binding pocket distortions and a linker-punctured tunnel to the protein exterior at a region incompatible with E3 complex formation, highlighting the effects of linker environment on PROTAC activity.

Citing Articles

First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy.

Huber A, Jung Y, Li Y, Lin W, Wu J, Poudel S J Med Chem. 2024; 67(20):18549-18575.

PMID: 39405362 PMC: 11584202. DOI: 10.1021/acs.jmedchem.4c01926.

References
1.
Nabet B, Ferguson F, Seong B, Kuljanin M, Leggett A, Mohardt M . Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat Commun. 2020; 11(1):4687. PMC: 7501296. DOI: 10.1038/s41467-020-18377-w. View

2.
Chrencik J, Orans J, Moore L, Xue Y, Peng L, Collins J . Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol. 2005; 19(5):1125-34. DOI: 10.1210/me.2004-0346. View

3.
Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D . A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019; 36(5):498-511.e17. PMC: 6880868. DOI: 10.1016/j.ccell.2019.10.002. View

4.
Han X, Zhao L, Xiang W, Qin C, Miao B, Xu T . Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J Med Chem. 2019; 62(24):11218-11231. DOI: 10.1021/acs.jmedchem.9b01393. View

5.
Smith B, Wang S, Jaime-Figueroa S, Harbin A, Wang J, Hamman B . Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun. 2019; 10(1):131. PMC: 6328587. DOI: 10.1038/s41467-018-08027-7. View